ArticleJournal of healthcare engineering2022
Application of Esmolol to Control Heart Rate and Artificial Intelligence Reconstruction Analysis for Rapid Zero-Cooperation Emergency Coronary CTA.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate a rapid and effective method for the examination of coronary CTA in emergency patients requiring coronary CTA examination, who have faster heart rate (≧80 bpm) or cannot cooperate with the examination due to the inability of breath holding at poor physical conditions. Methods: Before coronary CTA examination, with the ECG monitoring, intravenous injection of esmolol was given to achieve rapid heart rate reduction. Without the patient's cooperation, coronary CTA examination was then performed in a quick and effective manner using the 640-slice high-speed CT. The diagnosis report was obtained through the subsequent reconstruction analysis using artificial intelligence software. Conclusion: Esmolol injection can rapidly reduce the heart rate of normal people during exercise and at rest, and the steady blood concentration can be reached in 2 minutes. The half-life is about 5 minutes, with short duration and fewer side effects on patients. The diagnostic rate of coronary artery segment using (excellent + good) CTA image of the patients with esmolol and artificial intelligence analysis in the experimental group was 95.4%, while the diagnostic rate was 91.1% in the control group, and there was no significant statistical difference between the two groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.